Q4 2025 EPS Estimates for Pfizer Inc. (NYSE:PFE) Boosted by Zacks Research

Pfizer Inc. (NYSE:PFE) – Stock analysts at Zacks Research lifted their Q4 2025 earnings estimates for Pfizer in a research report issued on Wednesday, June 26th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings per share of $0.78 for the quarter, up from their previous forecast of $0.76. The consensus estimate for Pfizer’s current full-year earnings is $2.38 per share. Zacks Research also issued estimates for Pfizer’s FY2026 earnings at $2.85 EPS.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the company earned $1.23 earnings per share. The business’s revenue was down 19.5% compared to the same quarter last year.

Several other equities analysts have also recently weighed in on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $35.54.

Pfizer Price Performance

Shares of PFE opened at $27.98 on Friday. Pfizer has a twelve month low of $25.20 and a twelve month high of $37.80. The company has a market capitalization of $158.55 billion, a P/E ratio of -466.26, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. The firm has a 50 day moving average of $27.90 and a 200 day moving average of $27.68. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Hedge Funds Weigh In On Pfizer

Large investors have recently made changes to their positions in the company. Ironvine Capital Partners LLC boosted its stake in shares of Pfizer by 2.1% during the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after purchasing an additional 353 shares during the period. Advisor OS LLC increased its position in shares of Pfizer by 1.0% during the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after acquiring an additional 365 shares during the period. Safeguard Investment Advisory Group LLC raised its stake in shares of Pfizer by 3.9% during the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 371 shares in the last quarter. Lantz Financial LLC boosted its holdings in shares of Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after purchasing an additional 381 shares during the period. Finally, Wellington Shields Capital Management LLC increased its holdings in Pfizer by 1.3% during the 1st quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock worth $853,000 after purchasing an additional 385 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.